



# Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value

## Questions for Deliberation and Voting: March 26, 2021 Public Meeting

*These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.*

**Patient Population for all questions:** *Adult (18 years and older) patients with Class III, IV, or V lupus nephritis*

### Clinical Evidence

1. Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of **belimumab (Benlysta®) plus standard induction therapy** is superior to that provided by **standard induction therapy alone**?

Yes

No

2. Given the currently available evidence, is the evidence adequate to demonstrate that the net health benefit of **voclosporin (Lupkynis™) plus standard induction therapy** is superior to that provided by **standard induction therapy alone**?

Yes

No

## Potential Other Benefits and Contextual Considerations

Please vote on the following contextual considerations for both treatments under review:

**Question: When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for lupus nephritis, on the basis of the following contextual considerations:**

1= Very low priority; 2 = Low priority; 3 = Average priority; 4 = High priority; 5= Very high priority

1. Short-term risk of death for patients without treatment
2. Magnitude of the lifetime impact on individual patients of the condition being treated
3. Other (as relevant):

Please vote separately for each treatment on the following potential other benefits or disadvantages:

**Question: What are the relative effects of BELIMUMAB versus standard induction therapy for lupus nephritis on the following outcomes that inform judgment of the overall long-term value for money of BELIMUMAB?**

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

1. Patients' ability to achieve major life goals related to education, work, or family life
2. Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
3. Patients' ability to manage and sustain treatment given the complexity of regimen
4. Health inequities
5. Other: Preservation of kidney function improves the chances for patients to have children, belimumab's potential broader effect on improving SLE

**Question: What are the relative effects of VOCLOSPORIN versus standard induction therapy for lupus nephritis on the following outcomes that inform judgment of the overall long-term value for money of VOCLOSPORIN?**

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

6. Patients' ability to achieve major life goals related to education, work, or family life
7. Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
8. Patients' ability to manage and sustain treatment given the complexity of regimen
9. Health inequities
10. Other: Preservation of kidney function improves the chances for patients to have children

## Long-Term Value for Money

1. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with **belimumab** versus standard induction therapy?
  - a. Low long-term value for money at current price
  - b. Intermediate long-term value for money at current price
  - c. High long-term value for money at current price
  
2. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with **voclosporin** versus standard induction therapy?
  - d. Low long-term value for money at assumed price
  - e. Intermediate long-term value for money at assumed price
  - f. High long-term value for money at current assumed price